First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[18F]Flubatine

NeuroImage

Volumn 118, Issue , 2015, Pages 199-208

  Sabri, Osama ^a   Becker, Georg Alexander ^a   Meyer, Philipp M ^a   Hesse, Swen ^a   Wilke, Stephan ^a   Graef, Susanne ^a,b   Patt, Marianne ^a   Luthardt, Julia ^a   Wagenknecht, Gudrun ^c   Hoepping, Alexander ^d   Smits, René ^d   Franke, Annegret ^e   Sattler, Bernhard ^a   Habermann, Bernd ^a   Neuhaus, Petra ^e   Fischer, Steffen ^f   Tiepolt, Solveig ^a   Deuther Conrad, Winnie ^f   Barthel, Henryk ^a   Schönknecht, Peter ^a   Brust, Peter ^f   more..

^a UNIVERSITY OF LEIPZIG   (Germany)

^b MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

^d ABX Advanced Biochemical Compounds GmbH   (Germany)

^e Clinical Trials Centre Leipzig (ZKS)   (Germany)

^f INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

( ) 18F Flubatine ( ) 18F NCFHEB ; Human brain; Kinetic modeling; PET; 4 2* nicotinic acetylcholine receptors

Indexed keywords

FLUBATINE F 18; NICOTINIC RECEPTOR ALPHA4BETA2; RADIOLIGAND; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; FLUORONORCHLOROEPIBATIDINE; FUSED HETEROCYCLIC RINGS; NICOTINIC RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CHEMICAL BINDING; CORPUS CALLOSUM; FRONTAL CORTEX; HUMAN; IN VIVO STUDY; MALE; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RADIOACTIVITY; RELIABILITY; THALAMUS; BLOOD; BRAIN; METABOLISM; MIDDLE AGED; PROCEDURES; SCINTISCANNING;

AGED; BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, NICOTINIC;

EID: 84934988835     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2015.05.065     Document Type: Article

References (57)

1. Bai D., Xu R., Chu G., Zhu X. Synthesis of (+/-)-epibatidine and its analogues. J. Org. Chem. 1996, 61:4600-4606.
2. Becker G., Wilke S., Schoenknecht P., Patt M., Luthardt J., Hesse S., Wagenknecht G., Hoepping A., Brust P., Sabri O. PET quantification of (-)-[F-18]-flubatine binding to nicotinic alpha4beta2 acetylcholine receptors in human brains. J. Cereb. Blood Flow Metab. 2012, 32:S172-S173.
3. Bertoldo A., Cobelli C. Physiological modelling of positron emission tomography images. Modelling Methodology for Physiology and Medicine 2014, 417-448. Elsevier, London. 2nd ed. E. Carson, C. Cobelli (Eds.).
4. 18F]FA) in the living human brain of smokers with paranoid schizophrenia. Synapse 2012, 66:352-368.
5. Brody A.L., Mandelkern M.A., London E.D., Olmstead R.E., Farahi J., Scheibal D., Jou J., Allen V., Tiongson E., Chefer S.I., Koren A.O., Mukhin A.G. Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors. Arch. Gen. Psychiatry 2006, 63:907-915.
6. 18F]norchloro-fluoro-homoepibatidine. Synapse 2008, 62:205-218.
7. Burnham K.P., Anderson D.R. Model Selection and Multimodel Inference: A Practical Information Theoretic Approach 2002, 70-75. Springer, New York, NY. 2nd ed.
8. Changeux J.-P., Edelstein S.J. Nicotinic Acetylcholine Receptors 2005, 192-211. Odile Jacob Publishing Corporation, New York, NY.
9. 123I]iodo-A-85380 using single photon emission computed tomography. Life Sci. 1998, 63:L355-L360.
10. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 2007, 47:699-729.
11. Deuther-Conrad W., Patt J.T., Feuerbach D., Wegner F., Brust P., Steinbach J. Norchloro-fluoro-homoepibatidine: specificity to neuronal nicotinic acetylcholine receptor subtypes in vitro. Farmaco 2004, 59:785-792.
12. Deuther-Conrad W., Patt J.T., Lockman P.R., Allen D.D., Patt M., Schildan A., Ganapathy V., Steinbach J., Sabri O., Brust P. Norchloro-fluoro-homoepibatidine (NCFHEB) - a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. Eur. Neuropsychopharmacol. 2008, 18:222-229.
13. 18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse 2004, 53:184-189.
14. Doll F., Dolci L., Valette H., Hinnen F., Vaufrey F., Guenther I., Fuseau C., Coulon C., Bottlaender M., Crouzel C. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. J. Med. Chem. 1999, 42:2251-2259.
15. D'Souza D.C., Esterlis I., Carbuto M., Krasenics M., Seibyl J., Bois F., Pittman B., Ranganathan M., Cosgrove K., Staley J. Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am. J. Psychiatry 2012, 169:326-334.
16. Fischer S., Hiller A., Smits R., Hoepping A., Funke U., Wenzel B., Cumming P., Sabri O., Steinbach J., Brust P. Radiosynthesis of racemic and enantiomerically pure (-)-[18F]flubatine-a promising PET radiotracer for neuroimaging of α4β2 nicotinic acetylcholine receptors. Appl. Radiat. Isot. 2013, 74:128-136.
17. Fujita M., Ichise M., Zoghbi S.S., Liow J.S., Ghose S., Vines D.C., Sangare J., Lu J.Q., Cropley V.L., Iida H., Kim K.M., Cohen R.M., Bara-Jimenez W., Ravina B., Innis R.B. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann. Neurol. 2006, 59:174-177.
18. Gallezot J.D., Esterlis I., Bois F., Zheng M.Q., Lin S.F., Kloczynski T., Krystal J.H., Huang Y., Sabri O., Carson R.E., Cosgrove K.P. Evaluation of the sensitivity of the novel α4β2* nicotinic acetylcholine receptor PET radioligand (18) F-(-)-NCFHEB to increases in synaptic acetylcholine levels in rhesus monkeys. Synapse 2014, 68:556-564.
19. 18F-labelled fluoromethyl-McN5652 and PET in humans. Eur. J. Nucl. Med. Mol. Imaging 2012, 39:1001-1011.
20. Hillmer A.T., Wooten D.W., Moirano J.M., Slesarev M., Barnhart T.E., Engle J.W., Nickles R.J., Murali D., Schneider M.L., Mukherjee J., Christian B.T. Specific α4β2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey. Synapse 2011, 65:1309-1318.
21. 18F]Flubatine: evaluation in rhesus monkeys and a report of the first fully automated radiosynthesis validated for clinical use. J. Label. Compd. Radiopharm. 2013, 56:595-599.
22. Horti A.G., Villemagne V.L. The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr. Pharm. Des. 2006, 12:3877-3900.
23. 18F]Fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors. Nucl. Med. Biol. 1998, 25:599-603.
24. Horti A.G., Gao Y., Kuwabara H., Dannals R.F. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci. 2010, 86:575-584.
25. Horti A.G., Kuwabara H., Holt D.P., Dannals R.F., Wong D.F. Recent PET radioligands with optimal brain kinetics for imaging nicotinic acetylcholine receptors. J. Label. Compd. Radiopharm. 2013, 56:159-166.
26. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
27. Kas A., Bottlaender M., Gallezot J.D., Vidailhet M., Villafane G., Grégoire M.C., Coulon C., Valette H., Dollé F., Ribeiro M.J., Hantraye P., Remy P. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J. Cereb. Blood Flow Metab. 2009, 29:1601-1608.
28. Kendziorra K., Wolf H., Meyer P.M., Barthel H., Hesse S., Becker G.A., Luthardt J., Schildan A., Patt M., Sorger D., Seese A., Gertz H.J., Sabri O. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:515-525.
29. 18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J. 2003, 17:1331-1333.
30. 18F-AZAN, a radioligand with improved brain kinetics. J. Nucl. Med. 2012, 53:121-129.
31. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J., Christman D.R. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990, 10:740-747.
32. 123I-5IA SPECT. J. Nucl. Med. 2004, 45:1458-1470.
33. 3H]epibatidine. Brain Res. 1998, 801:143-149.
34. Meyer P.M., Strecker K., Kendziorra K., Becker G., Hesse S., Woelpl D., Hensel A., Patt M., Sorger D., Wegner F., Lobsien D., Barthel H., Brust P., Gertz H.J., Sabri O., Schwarz J. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch. Gen. Psychiatry 2009, 66:866-877.
35. Mihailescu S., Drucker-Colín R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch. Med. Res. 2000, 31:131-144.
36. Mo Y.-X., Yin Y.-F., Li Y.-M. Neural nAChRs PET imaging probes. Nucl. Med. Commun. 2014, 35:135-143.
37. 18F-FA-85380. J. Nucl. Med. 2008, 49:1628-1635.
38. 123I-5IA-85380 single-photon-emission computed tomography. J. Neurol. Neurosurg. Psychiatry 2007, 78:356-362.
39. Okada H., Ouchi Y., Ogawa M., Futatsubashi M., Saito Y., Yoshikawa E., Terada T., Oboshi Y., Tsukada H., Ueki T., Watanabe M., Yamashita T., Magata Y. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Brain 2013, 136:3004-3017.
40. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 2000, 61:75-111.
41. 18F-labelling and evaluation of affinity and selectivity at neuronal nicotinic acetylcholine receptors. J. Label. Compd. Radiopharm. 2003, 46(S1):168.
42. 18F]Flubatine under GMP conditions for human application. Appl. Radiat. Isot. 2013, 80:7-11.
43. 18F]Flubatine in humans. Nucl. Med. Biol. 2014, 41:489-494.
44. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995, 64:385-395.
45. Picard F., Bruel D., Servent D., Saba W., Fruchart-Gaillard C., Schöllhorn-Peyronneau M.A., Roumenov D., Brodtkorb E., Zuberi S., Gambardella A., Steinborn B., Hufnagel A., Valette H., Bottlaender M. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain 2006, 129:2047-2060.
46. Rinne J.O., Myllykylä T., Lönnberg P., Marjamäki P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. 1991, 547:167-170.
47. Sabri O., Kendziorra K., Wolf H., Gertz H.J., Brust P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(Suppl. 1):S30-S45.
48. Sabri O., Wilke S., Graef S., Becker G., Hesse S., Sattler B., Schoenknecht P., Wagenknecht G., Smits R., Hoepping A., Steinbach J., Brust P. PET imaging of cerebral nicotinic acetylcholine receptors (nAChRs) in early Alzheimer's disease (AD) assessed with the new radioligand (-)-[F-18]-norchloro-fluoro-homoepibatidine ([F-18]Flubatine). J. Cereb. Blood Flow Metab. 2012, 32:S55.
49. Saricicek A., Esterlis I., Maloney K.H., Mineur Y.S., Ruf B.M., Muralidharan A., Chen J.I., Cosgrove K.P., Kerestes R., Ghose S., Tamminga C.A., Pittman B., Bois F., Tamagnan G., Seibyl J., Picciotto M.R., Staley J.K., Bhagwagar Z. Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am. J. Psychiatry 2012, 169:851-859.
50. 18F-flubatine, comparing animal model data sets of mice and piglets with first-in-man results. J. Nucl. Med. 2014, 55:1885-1892.
51. 18F]Fluoro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor. Nucl. Med. Biol. 2000, 27:51-56.
52. 18F]F-A-85380). Appl. Radiat. Isot. 2007, 65:1244-1248.
53. Smits R., Fischer S., Hiller A., Deuther-Conrad W., Wenzel B., Patt M., Cumming P., Steinbach J., Sabri O., Brust P., Hoepping A. Synthesis and biological evaluation of both enantiomers of [(18)F]flubatine, promising radiotracers with fast kinetics for the imaging of α4β2-nicotinic acetylcholine receptors. Bioorg. Med. Chem. 2014, 22:804-812.
54. 18F]fluoro-A-85380 to plasma proteins. Nucl. Med. Biol. 2006, 33:899-906.
55. Staley J.K., Krishnan-Sarin S., Cosgrove K.P., Krantzler E., Frohlich E., Perry E., Dubin J.A., Estok K., Brenner E., Baldwin R.M., Tamagnan G.D., Seibyl J.P., Jatlow P., Picciotto M.R., London E.D., O'Malley S., van Dyck C.H. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J. Neurosci. 2006, 26:8707-8714.
56. Turkheimer F.E., Hinz R., Cunningham V.J. On the undecidability among kinetic models: from model selection to model averaging. J. Cereb. Blood Flow Metab. 2003, 23:490-498.
57. 18F-AZAN, a radioligand with optimal brain kinetics. J. Nucl. Med. 2013, 54:1308-1314.